Most RA Patients Meet EMA's JAK Inhibitor Warning Criteria
Recent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK inhibitors unless there is no other alternative.
Source: medscape.com
Maya Buch News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Maya Buch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Maya Buch Today - Breaking & Trending Today
Irish rheumatology committee formed as part of global initiative focused on achieving treat-to-target goals
AbbVie has announced that an Irish committee of rheumatology experts is coming together as part of a global initiative seeking solutions to the challenges
Source: imt.ie
Nuances in Efficacy, MACE Risk Revealed Between JAKi, TNFi
Three studies provide more data on risk for major adverse cardiovascular events with JAK inhibitors vs TNF inhibitors, as well as their efficacy in patients with different levels of risk.
Source: medscape.com
Cardiovascular considerations in RA
Patients with rheumatoid arthritis (RA) are at higher risk for cardiovascular disease than the general population. Systemic inflammation mediates some of this increased risk, therefore it seems logical that treatment with disease-modifying antirheumatic drugs (DMARDs) may be beneficial. A number of abstracts presented at the 2023 annual congress of EULAR – the European Alliance of Associations for Rheumatology – looked at cardiovascular data in RA.
Source: eurekalert.org
Cardiovascular comobidities in RA patients
The increased cardiovascular risks in RA include acute coronary syndromes (ACS). The extent to which DMARD-induced remission could reduce the risk of ACS in RA versus rates in the general population – and whether there are DMARD-specific beneficial effects on ACS risk – remain unknown.
Source: news-medical.net